Journal
DRUGS
Volume 79, Issue 16, Pages 1819-1828Publisher
ADIS INT LTD
DOI: 10.1007/s40265-019-01211-z
Keywords
-
Categories
Ask authors/readers for more resources
Upadacitinib (Rinvoq (TM)), an orally-administered Janus kinase 1 (JAK-1) inhibitor, is being developed by AbbVie for the treatment of rheumatoid arthritis. In August 2019, based on positive results from multinational phase III trials conducted in patients with rheumatoid arthritis, upadacitinib received marketing approval in the USA for the treatment of moderately to severely active rheumatoid arthritis and an inadequate response or intolerance to methotrexate. This article summarizes the milestones in the development of upadacitinib leading to this first approval for the treatment of rheumatoid arthritis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available